121859-57-2

Usage

Uses

Used in Pharmaceutical Research:
5,6-Dichloroindole is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its indole structure is a key component in the development of new drugs, making it an essential tool in medicinal chemistry.
Used in Chemical Research:
5,6-Dichloroindole is employed as a reagent in various chemical reactions, allowing for the modification and functionalization of the indole ring. This enables the exploration of new chemical properties and potential applications in different fields.
Used in Drug Development:
5,6-Dichloroindole is used as a lead compound in the discovery and optimization of new therapeutic agents. Its indole structure provides a versatile scaffold for the design of novel drugs with potential biological activities.
Used in Material Science:
5,6-Dichloroindole is utilized in the synthesis of indole-based materials, such as organic semiconductors and conducting polymers, which have potential applications in electronic devices and sensors.
Note: Due to the toxicity of 5,6-dichloroindole, it is crucial to handle 5,6-DICHLOROINDOLE with caution and follow appropriate safety protocols during its use in research and development.

InChI:InChI=1/C8H5Cl2N/c9-6-3-5-1-2-11-8(5)4-7(6)10/h1-4,11H

Upstream product

• 7494-45-3 1,2-dichloro-4-methyl-5-nitrobenzene 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 6374-92-1 5,7-dichloroisatin 
• 95-75-0 3,4-Dichlorotoluene 
• 229481-09-8 (E)-2-(4,5-dichloro-2-nitrophenyl)-N,N-dimethylethenamine 

Downstream Products

• 98640-00-7 2-(5,6-dichloro-1H-indol-3-yl)acetic acid 
• 1404532-74-6 {3-[4-(4-butyryl-5-methyl-pyrazol-1-yl)phenylcarbamoyl]-5,6-dichloro-indol-1-yl}acetic acid methyl ester 
• 1404533-09-0 sodium {3-[4-(4-butyryl-5-methyl-pyrazol-1-yl)phenylcarbamoyl]-5,6-dichloro-indol-1-yl}acetate 
• 1404535-81-4 C₃₀H₃₂Cl₂N₆O₃*ClH 
• 1677-48-1 5,6-dichloroisatin 
• 1209183-93-6 tert-butyl 5,6-dichloro-1H-indole-1-carboxylate 
• 1266605-89-3 (2R,3R)-2-(2,4-difluorophenyl)-3-[4-(5,6-dichloro-1H-indol-3-ylmethyl)-piperazin-1-yl]-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 

Relevant academic research and scientific papers

METHODS USING HDAC11 INHIBITORS

The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

One-pot tandem synthesis of 2,3-unsubstituted indoles, an improved Leimgruber-Batchoindole synthesis

A concise, fast and efficient one-pot methodology has been developed for preparing 2,3-unsubstituted indoles from 2-nitrotoluenes and dimethylformamide dimethyl acetal. Compared with the classical Leimgruber-Batcho reaction, such a one-pot process simplified the operation procedures, generated less by-products and chemical residues, and resulted in higher overall yields in a shorter reaction time.

4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents

This invention relates to certain 4-aminoquinazolines and the pharmaceutically acceptable salts and stereoisomers thereof, the formula whereof are described herein. The compounds are useful for the treatment of hyperproliferative diseases, particularly as anti-cancer agents.

Novel and selective 5-HT(2C/2B) receptor antagonists as potential anxiolytic agents: Synthesis, quantitative structure - Activity relationships, and molecular modeling of substituted 1-(3- pyridylcarbamoyl)indolines

The synthesis, biological activity, and molecular modeling of a novel series of substituted 1-(3-pyridylcarbamoyl)indolines are reported. These compounds are isosteres of the previously published indole urea 1 (SB- 206553) and illustrate the use of aromatic disubstitution as a replacement for fused five-membered rings in the context of 5-HT(2C/2B) receptor antagonists. By targeting a region of space previously identified as sterically allowed at the 5-HT(2C) receptor but disallowed at the 5-HT(2A) receptor, we have identified a number of compounds which are the most potent and selective 5-HT(2C/2B) receptor antagonists yet reported. 46 (SB-221284) was selected on the basis of its overall biological profile for further evaluation as a novel, potential nonsedating anxiolytic agent. A CoMFA analysis of these compounds produced a model with good predictive value and in addition good qualitative agreement with both our 5-HT(2C) receptor model and our proposed binding mode for this class of ligands within that model.